UAB
Birmingham, Alabama, 35294, United States
Location status: Recruiting
Location contact
Evan Hudson, BS
CONTACT
Jonathan McConathy, MD,PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06289582
The overall goal of this protocol is to investigate [18F]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in [18F]DPA-714 binding in PD participants during a 24-month interval.
Primary Objectives
* To compare [18F]DPA-714 binding in prodromal and manifest PD and healthy volunteers. * To determine the longitudinal change in [18F]DPA-714 during a 24-month interval for prodromal and early initially untreated PD participants.
Secondary Objectives
* To evaluate the correlation between baseline [18F]DPA-714 and PPMI clinical and biomarker outcomes. * To evaluate the correlation between the longitudinal change of [18F]DPA-714 and PPMI clinical and biomarker outcomes * To acquire safety data following injection of [18F]DPA-714
Interested in participating?
Request Info18 year–99 year
All sexes
Interventional
Early Phase 1
Birmingham, Alabama, 35294, United States
Location status: Recruiting
Evan Hudson, BS
CONTACT
Jonathan McConathy, MD,PhD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
brain PET/MRI imaging after [F-18]DPA-714 administration
Time frame: 24 months
The changes over time in neuroinflammation based on TSPO will be assessed by comparing TSPO-PET imaging at baseline, 12 months and 24 months after enrollment.
Contact information is provided by the study sponsor or research team.
University of Alabama at Birmingham
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01734122
Basal Ganglia Diseases, Brain Diseases
Nashville, Tennessee, United States
View Trial DetailsNCT05266872
Basal Ganglia Diseases, Brain Diseases
Luxembourg
View Trial DetailsNCT06518824
Basal Ganglia Diseases, Brain Diseases
Vancouver, British Columbia, Canada
View Trial DetailsNCT05101161
Basal Ganglia Diseases, Brain Diseases
Zurich, Canton of Zurich, Switzerland
View Trial Details